ESSA Pharma Inc.
EPIX
$1.72
$0.010.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.21M | 13.21M | 11.63M | 11.10M | 10.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.51M | 34.42M | 33.88M | 34.15M | 31.87M |
| Operating Income | -36.51M | -34.42M | -33.88M | -34.15M | -31.87M |
| Income Before Tax | -31.11M | -28.54M | -27.67M | -27.73M | -25.80M |
| Income Tax Expenses | -- | -- | 0.00 | 0.00 | 1.60K |
| Earnings from Continuing Operations | -31.11 | -28.54 | -27.67 | -27.73 | -25.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.11M | -28.54M | -27.67M | -27.73M | -25.80M |
| EBIT | -36.51M | -34.42M | -33.88M | -34.15M | -31.87M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.70 | -0.64 | -0.63 | -0.63 | -0.59 |
| Normalized Basic EPS | -0.44 | -0.40 | -0.39 | -0.39 | -0.37 |
| EPS Diluted | -0.70 | -0.64 | -0.63 | -0.63 | -0.59 |
| Normalized Diluted EPS | -0.44 | -0.40 | -0.39 | -0.39 | -0.37 |
| Average Basic Shares Outstanding | 177.36M | 177.10M | 176.82M | 176.55M | 176.41M |
| Average Diluted Shares Outstanding | 177.36M | 177.10M | 176.82M | 176.55M | 176.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |